452 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; the company’s
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
sales impacted by inventory & gross-to-net dynamics ‒ Momentum strengthening in new patient starts International expansion based on reimbursement timing
8-K
EX-1.1
sob0d7n5kdlrtoo
22 Feb 24
Other Events
4:15pm
424B5
20y0wsp mix
16 Feb 24
Prospectus supplement for primary offering
4:34pm
424B2
ymh r1l1bqcws
13 Feb 24
Prospectus for primary offering
8:00am
8-K
EX-99.1
c8hu2cddfa0waf16kohi
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
8-K
EX-99.2
h2d6 t1cd
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
dglq1h843cy5b
25 Jan 24
Third party tender offer statement
8:13am
8-K
EX-1.1
7rbyx0119 muvglw
13 Nov 23
Other Events
4:19pm
424B5
hldavl 6835w
1 Nov 23
Prospectus supplement for primary offering
4:16pm
424B3
khzv6uvyn63nhe7sb
30 Oct 23
Prospectus supplement
8:05am
8-K
EX-99.1
23fuxp64pd 08sa
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.2
60sxooj11ocd rp7w4
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am